Henlius Posts 27% Revenue Growth, Accelerates Global Expansion — Shanghai Henlius Biotech, Inc.

Event summary

Henlius reported RMB 3.5882 billion in revenue for H1 2026, up 27.3% YoY, with net profit increasing 10.3% YoY to RMB 430.4 million.
Non-IFRS profit rose 46.7% YoY to RMB 572.3 million, and adjusted EBITDA increased 35.2% YoY to RMB 904.1 million.
Global product sales reached RMB 2.9386 billion, with ex-China sales revenue surging 159.4% YoY to RMB 105.3 million.
Serplulimab gained approval in China for perioperative gastric cancer treatment, becoming the first and only anti-PD-1 mAb globally for this indication.
Henlius established strategic partnerships with Eisai, Abbott, and Sandoz to expand its global commercialization footprint.

The big picture

Henlius' strong H1 2026 results underscore its dual-engine growth model, combining global commercialization with pipeline innovation. The company's strategic partnerships and regulatory milestones reflect its accelerating shift toward a China-headquartered multinational biopharmaceutical model. As Henlius aims to bring 10 new products to market by 2030, its ability to execute on its Globalization 2.0 strategy will be critical in maintaining its competitive edge in the biopharmaceutical industry.

What we're watching

Pipeline Progress: The pace at which Henlius advances its innovative pipeline, particularly HLX43 and dulpatatug, will determine its long-term competitive positioning.
Global Commercialization: How effectively Henlius leverages its partnerships with Eisai, Abbott, and Sandoz to penetrate high-value and emerging markets.
Regulatory Momentum: Whether Henlius can sustain its regulatory approval momentum, particularly for its biosimilar portfolio, to support its C-MNC ambitions.